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Abstract
Background: Chronic HCV is one of the major causes of morbidity and mortality in the present day world. The
assessment of disease progression not only provides useful information for diagnosis and therapeutic supervision
judgment but also for monitoring disease. Different invasive and non invasive methods are applied to diagnose
the disease from initial to end stage (mild fibrosis to cirrhosis). Although, liver biopsy is still considered as gold
standard to identify liver histological stages, an assessment of the disease development based on non-invasive
clinical findings is also emerging and this may replace the need of biopsy in near future. This review gives brief
insight on non-invasive methods currently available for predicting liver fibrosis in HCV with their current pros and
cons to make easier for a clinician to choose better marker to assess liver fibrosis in HCV infected patients.
Methods: More than 200 studies regarding invasive and noninvasive markers available for HCV liver disease
diagnosis were thoroughly reviewed. We examined year wise results of these markers based on their sensitivity,
specificity, PPV, NPV and AUROCs.
Results: We found that in all non-invasive serum markers for HCV, FibroTest, Forn’s Index, Fibrometer and
HepaScore have high five-year predictive value but with low AUROCs (0.60~0.85) and are not comparable to liver
biopsy (AUROC = 0.97). Even though from its beginning, Fibroscan is proved to be best with high AUROCs (> 0.90)
in all studies, no single noninvasive marker is able to differentiate all fibrosis stages from end stage cirrhosis.
Meanwhile, specific genetic markers may not only discriminate fibrotic and cirrhotic liver but also differentiate
individual fibrosis stages.
Conclusions: There is a need of marker which accurately determines the stage based on simplest routine
laboratory test. Genetic marker in combination of imaging technique may be the better non invasive diagnostic
method in future.
1. Introduction
Chronic Hepatitis C (HCV) is one of the major causes
of liver fibrosis, with distortion of the hepatic architec-
ture, and ultimate progression to cirrhosis. Approxi-
mately more than 3% of the total world population is
chronically infected with HCV and due to gradual
increase in the prevalence of HCV; future burden of
chronic HCV is predicted to raise at least 3 fold by the
year 2020. Common causes of liver fibrosis are viral
hepatitis and steato hepatitis with alcohol or obesity.
Fibrosis caused by excessive deposition of extracellular
matrix (ECM) by histological and molecular reshuffling
of various components like collagens, glycoproteins, pro-
teoglycans, matrix proteins and matrix bound growth
factors. These changes can lead to metabolic and synth-
esis impairment to hepatocytes, epithelial cells and
hepatic stellate cells (HSC). HSC activation the main
step leading to fibrosis, involves several changes in liver
like fibrogenesis, proliferation, contractility, chemotaxis,
matrix degradation and cytokine release. Fibrosis can be
defined as net result of the balance between ECM pro-
duction and degradation. As ECM tissues not only
involve matrix production but also matrix degradation
leading to ECM remodeling, fibrosis is potentially a
reversible process in early stages (advance stages in
some cases) [1-6].
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response but also reflect/indicate cirrhosis development
disaster. We can evaluate fibrosis in HCV infected
patients invasively or non-invasively. Liver biopsy an
invasive method is used for histological scoring and still
used as reference test for fibrosis staging. With the
increasing knowledge of molecular biology, genetics and
availability of modern imaging techniques, many clini-
cians and related scientists developed several non-
invasivemethods to assess liver fibrosis and cirrhosis.
These markers need to be more precise, reproducible
and non-invasive to evaluate liver fibrosis in HCV
infected patients. Therefore, an assessment of the disease
development based on clinical findings is still critical for
patients infected with HCV. The accuracy of a serological
test either individually or in combination is given as the
area under the curve (AUC) of the receiver operator
characteristic (ROC) of specific serum diagnosis test.
In the meantime, genetic marker should reflect
differential expression in different fibrosis stages [4,7-13].
This article will focus on the technologies that can be
used to assess hepatic fibrosis in HCV infected patients
with unequal values. Figure 1 shows an outline of possi-
ble methods used for fibrosis evaluation in HCV infected
patients.
2. Invasive Method
In clinical practice, grading and staging involve semi-quan-
titative scoring systems, and elementary lesion expressed
as a numerical value [14,15]. Three scoring systems, Kno-
dell, Ishak and Metavir are extensively used to assess fibro-
sis [16-18]. In Metavir system, one of the most clinically
validated systems; F0-F1 is considered none to mild, F2-F3
moderate to advance fibrosis and F4 as cirrhosis. Liver
biopsy, an invasive method is considered the gold standard
to identify liver fibrosis. Unfortunately, procedure of liver
biopsy is invasive, expensive with severe side effects lead-
ing to death and not suitable for all patients. Other
Figure 1 Schematic diagram of noninvasive methods used to assess liver fibrosis and cirrhosis in HCV or co-infected patients.
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and inter observer variation and somehow static, not accu-
rately predict disease progression [19,20].
3. Non-invasive Methods
Non-invasive methods can be classified as serum,
genetic and imaging techniques. These markers are
addressed below in detail.
4. Serum markers
Serological markers refer to the measurement of one or
more molecules within blood or serum correlating to
hepatic fibrosis [21-23]. There are several proposed ser-
ological markers or combinations of serum markers for
hepatic fibrosis measurement. Their levels vary by
changes in their clearance, metabolism, and excretion,
and their significant contribution from non-hepatic
sources, such as, bones, joints, lungs, kidneys and skin
[24,25]. Proposed hepatic fibrosis serological markers
can be divided in three categories as direct, indirect or
composite. Combinations of both direct and indirect,
markers are taking place as an emerging and promising
alternative to liver biopsy [26-29]. Figure 1 gives a brief
idea about the non-invasive methods used for fibrosis
and cirrhosis prediction in HCV infected patients.
4.1. Direct serum markers
Direct serum markers reflect ECM turnover, balance
between hepatic fibrogenesis and fibrolysis, and in the
deposition and removal of ECM. Levels of direct serum
markers are elevated during disease progression and an
independent association between stage of fibrosis and
direct markers was observed [30-32]. Some of the mar-
kers reported are discussed below.
4.1.1. Matrix deposition and removal markers
These may be classified into following
Procollagen I carboxy terminal peptide (PICP), Pro-
collagen III amino-terminal peptide (PIIINP) and
Type IV collagen PICP and PIIINP released into the
serum during matrix removal and deposition. PIIINP
reflects the stage of fibrosis and known to be elevated in
chronic liver disease. PIIINP is a good inflammatory
score predictor as compared to fibrosis. PICP usually
indicates cirrhosis and used for quantifying disease
severity. However, it reflects alcohol etiology better than
diagnosis of chronic liver disease. Type IV serum col-
lagen reflects matrix degradation and increased in
chronic liver disease. Murawaki et al (1996) established
the cutoff value of 110 ng/mL for stages greater than F2
and 130 ng/mL for F3 fibrosis stage [33-37].
Matrix metalloproteinase (MMP’s) and tissue inhibi-
tor of metalloproteinases (TIMPs) MMP’se n z y m e sp r o -
duced intracellularly and secreted in a pro-enzyme form
that requires cleavage by cell surface mechanisms control
matrix degradation. Although these proteins act both to
degrade and deposition of ECM, also involve in activation
of growth factor, effect on cell proliferation and inhibition
of apoptosis; their association with liver fibrosis is not
clear [4,23]. TIMPs also increased during HCV infection,
while a decrease is reported after interferon therapy.
These have high diagnostic ability to detect cirrhosis [38].
Cytokines Two types of cytokines TGF-b 1( t r a n s f o r m -
ing growth factors b 1) and PDGF (platelet derived
growth factor) are mainly used to assess the fibrosis pro-
gression. TGF-b 1 is the dominant stimulus for produ-
cing extracellular matrix and it showed a significant
correlation with degree of hepatic fibrosis. A significant
association was found between TGF-b 1 serum levels
and fibrosis progression. Serum level of PDGF has also
showed high ability as serum marker for fibrosis pro-
gression [39-41].
4.1.2.Combined direct markers
FibroSpect FibroSpect assay is a combination of three
parameters: HA, TIMP-1 and alpha-2-macroglobulin
and can differentiate between no/mild and moderate/
severe fibrosis [42,43]. Maximum sensitivity and specifi-
city of this assay was observed at two extreme stages
(F0 and F4). This assay was further developed by adding
YKL-40 serum marker for assessing Ishak stages and
digital quantification of fibrosis [23].
ELF European liver fibrosis group (ELF) developed an
algorithm consisted of HA, PIIINP, TIMP-1 and age.
However this assay showed low performance while pre-
dicting fibrosis in chronic HCV patients [44].Leroy Score
This score was developed by Leroy et al and contains
PIIINP and MMP-1 as basic components. It can differ-
entiate between mild and significant fibrosis [45].
4.1.3.Others
Hyaluronic acid (HA) HA is best validated, an essential
component of extracellular matrix of body tissues. HA
levels increases with the fibrosis progression and corre-
late with the degree of fibrosis and inflammation in
chronic HCV patients. The diagnostic accuracy of HA is
better than that of PIIINP [32,35,46-49].
Chondrex, human cartilage glycoprotein (YKL-40) In
liver fibrosis, YKL-40 plays role in tissue degradation
and extracellular matrix remodeling. YKL-40 level is
observed to decrease after interferon therapy. In a com-
bination of different direct serum markers, HA and
YKL-40 were more useful for monitoring fibrosis pro-
gression with 80% PPV of predicting stage specific fibro-
sis. A significant association of HA with liver fibrosis
was observed when compared with TGF-b1 [50-53].
Table 1 briefly describes a year wise overview of the
AUROCs, PPV, NPV, sensitivity and specificity of direct
serum markers used in various studies to predict fibrosis
and cirrhosis in HCV infected patients. Direct serum mar-
kers; HA, YKL-40 and ELF were able to predict significant
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ever, these markers showed low sensitivity and NPV for
predicting fibrosis and high efficiency to detect cirrhosis.
5. Indirect serum fibrosis markers
The other category of serum marker is indirect markers
that are based on the disturbance of hepatic function or
structure.
5.1. Serum ALT, AST and AFP levels
Serum ALT released from liver tissue into the circula-
tion in proportion to the degree of hepatocellular
damage due to viral infections and toxic substances
[54,55]. ALT is thought as one of the more sensitive
marker of liver injury and disease progression [56-58].
However, ALT enzymatic activity may not always reflect
the degree of hepatic damage as about 26% patients
have persistently normal ALT levels but have a histolo-
gical score greater than A1F1 [59]. Serum AST levels
are most important predictor of histological activity
than ALT [60-62]. Serum AFP is alpha-1-globulin
secreted by fetal hepatocytes and fetal gastrointestinal
tract. Elevated serum AFP levels are associated with
acute and chronic HCV, toxic liver injury concentrations
and correlate with tumor size and decrease or normalize
after tumor removal. Elevated AFP levels are observed
in cirrhotic patients [63-66].
5.2. Platelet count (PLT)
Decreased production of thrombopoietin by hepatocytes
and reduced platelet production is associated with fibro-
sis progression. Platelet count (< 150 × 10
9/L < 100) can
differentiate cirrhotic (F4) from fibrosis (F1-F3) in
75-80% chronic HCV patients [67-70].
Table 1 Diagnostic accuracies of direct serum markers
Markers Study Year Prognosis Sen Spe PPV NVP AUC
ELF Score Rosenberg [44] 2004 Fibrosis 90 41 99 92 0.80
Cirrhosis - - - - 0.89
Cales [79] 2005 Fibrosis - - - - 0.88
Parkes [12] 2006 Fibrosis - - - - 0.78
Lee [107] 2010 Cirrhosis 0.70
FibroSpect Patel [42] 2004 Fibrosis 77 73 74 75 0.83
Cales [79] 2005 Fibrosis - - - - 0.87
Zaman [43] 2007 Fibrosis 72 74 61 82 0.82
HA Guechot [34] 1996 Fibrosis 64 91 - - 0.86
Cirrhosis 79 89 - - 0.92
Murawaki [47] 2001 Fibrosis 75 80 77 78 0.86
Cirrhosis 50 79 42 84 0.92
Halfon [49] 2005 Fibrosis 14 99 94 57 0.75
Cirrhosis 31 99 57 96 0.89
Suzuki [48] 2005 Fibrosis 85 80 51 96 0.89
Cirrhosis - - - - 0.92
Saitou [51] 2005 Fibrosis 80 80 80 80 0.92
Parise [81] 2006 Fibrosis 85 71 - - 0.88
Cirrhosis 91 82 - - 0.91
Leroy Score Leroy [45] 2004 Fibrosis 43 64 45 40 -
PIIINP Guechot [34] 1996 Fibrosis 70 63 - - 0.69
Cirrhosis 60 74 - - 0.73
Murawaki [47] 2001 Fibrosis 74 75 75 92 -
Cirrhosis 64 59 33 84 -
Saitou [51] 2005 Fibrosis 78 75 76 77 0.75
Cirrhosis 77 66 69 67 0.79
PIVNP Murawaki [47] 2001 Fibrosis 70 73 71 72 -
Cirrhosis 63 73 41 87 -
TIMP Murawaki [47] 2001 Fibrosis 79 56 63 73 -
Cirrhosis 82 54 34 94 -
Boeker [38] 2002 Fibrosis 52 88 - - 0.71
Cirrhosis 100 75 - - 0.90
YKL-40 Saitou [51] 2005 Fibrosis 78 81 80 79 0.81
Cirrhosis 80 71 73 78 0.80
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PT reflects the synthesis capacity of the liver and essen-
tial mechanism of blood coagulation. Its clinical refer-
ence range is usually around 12-15 seconds. Prolonged
PT is associated with esophageal varices and is one of
the earliest indicators of liver cirrhosis [71-73].
5.4. AST/ALT ratio (AAR)
Sheth et al. reported an AST/ALT ratio ≥ 1h a v i n g
100% PPV for the presence of cirrhosis in chronic HCV
patients [74]. Reedy et al. o b s e r v e dt h a tA A Rf a i l e dt o
predict cirrhosis accurately in HCV patients [75], while
Giannini et al. reported high diagnostic accuracy of the
AAR for prediction of cirrhosis in HCV infected patients
[76]. However, many authors could not able to find high
accuracy of this marker [4,70,77].
5.5. AST to platelet ratio Index (APRI)
APRI was the simplest and accurate test for significant
liver fibrosis and cirrhosis [28]. Several authors verified
this marker for fibrosis and cirrhosis and found it better
than AAR. However, APRI was unable to identify indivi-
dual stages of fibrosis [77-86].
5.6. PGA and PGAA Index
PGA was known to be the original index of hepatic
fibrosis in 1990 s and combines gamma glutamyl trans-
ferase (gGT), apolipoprotein A1 (PGA) and prothrombin
index. PGAA index is modified form of PGA index by
the addition of alpha-2-macroglobulin, resulted in its
improved version. The diagnostic accuracy of the PGA
and PGAA for detecting cirrhosis reported between 66-
72% and 80%, respectively [87-92].
5.7. FibroTest/FibroSure
FibroTest is the combination of five markers: alpha-2-
macroglobulin, haptoglobin, apolipoprotein A1, GGT
and total bilirubin [26,80]. This marker has 75% sensi-
tivity and 85% specificity with reproducibility for fibrosis
diagnosis [83-85]. However, Rossi et al. reported low
AUROC (0.739) for significant fibrosis with NPV and
PPV 85% and 78%, respectively. Meanwhile, FibroTest is
validated and suggested as an alternative to liver biopsy
in chronic HCV patients [93-105].
5.8. Fibro Index
It combines three markers; AST, platelet count and
gamma globulin. AUROC for prediction of significant
fibrosis was 0.83 [106].
5.9. Forns Index
This index is based on four available variables; age,
GGT, platelet count and cholesterol levels in a study
on HCV patients, included both test and validation
cohorts [27]. The limitation of this index was the iden-
tification of advance liver disease with minimal fibrosis
[79,80,106,107].
5.10. ActiTest
ActiTest reflects both necroinflamatory activity and liver
cirrhosis. It is modified form of Fibrotest with addition
of ALT level (26). Fibrotest and ActiTest were found to
be potential non-invasive assays for the assessment of
hepatic fibrosis and necro-inflammatory activity in
pediatric patients with chronic HCV in comparison with
liver biopsy [90,91,108].
5.11. SteatoTest
It incorporates the FibroTest, ALT, body mass index,
serum cholesterol, triglycerides and glucose adjusted for
age and gender. It has 63% PPV for steatosis prevalence
with 93% NPV [109].
5.12. Model 3
This model is based on AST, platelet count and pro-
thrombin time expressed as international normalized
ration (INR). Patients with liver cirrhosis can be excluded
at cutoff value of < 0.20 with 99% NPV [110,111].
5.13. Goteborg University Cirrhosis Index (GUCI)
Islam et al. found strong association between AST, pro-
thrombin-INR and platelet count. By using a cutoff
value 1.0, the sensitivity and specificity for the diagnosis
of cirrhosis was 80% and 78% respectively, while the
NPV and PPV were 97% and 31%, respectively [112].
5.14. Fibrosis Index
This index comprises of platelet count and albumin
contents. It can differentiate significant fibrosis and cir-
rhosis from mild fibrosis [113].
5.15. Phol Score
This index comprises of AST, ALT and platelet count. It
showed great accuracy for discriminating significant
fibrosis and cirrhosis with high PPV and NPV. However,
it showed limited ability to predict fibrosis in later study
[114,115].
5.16. Bonacini Index
This index incorporates ALT/AST ratio, INR and plate-
let count. It showed 94% specificity for predicting signif-
icant fibrosis in initial cohort [116].
Table 2 represents the diagnostic accuracies of indir-
ect serum markers. Indirect serum markers are easily
available and routinely used. These markers have the
ability to differentiate fibrosis and cirrhosis but lesser
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Markers Study Year Prognosis Sen Spe PPV NVP AUC
AAR Sheth [74] 1998 Cirrhosis 53 100 100 81 0.85
Afdhal [4] 2004 Fibrosis 47 - - 88 -
Cirrhosis - 96 74 - -
Lackner [70] 2005 Fibrosis 53 100 - - 0.57
Cirrhosis 36 90 41 87 0.73
Fuji [77] 2009 Fibrosis - - - - 0.56
ActiTest Imbert-Bismut [26] 2001 Fibrosis 91 42 - - 0.79
Halfon [100] 2008 Fibrosis 90 38 - - 0.75
APRI Wai [28] 2003 Fibrosis 41 95 64 90 0.88
Cirrhosis - - 57 - 0.94
Cales [79] 2005 Fibrosis - - - - 0.79
Bourliere [80] 2006 Fibrosis 22 95 63 76 0.71
Cirrhosis 38 96 96 40 0.81
Parise [81] 2006 Fibrosis 85 66 - - 0.82
Cirrhosis 73 81 - - 0.84
De Ledinghen [82] 2006 Cirrhosis - - - - 0.73
Halfon [83] 2007 Fibrosis 77 66 61 80 0.76
Cirrhosis 100 83 18 100 0.92
Leroy [84] 2008 Fibrosis 39 95 88 62 0.79
Cales [85] 2008 Fibrosis 62 83 80 67 0.78
Cirrhosis - - - - 0.84
Kamphues [86] 2010 Fibrosis 70 63 80 80 0.68
Cirrhosis 89 44 14 97 0.63
Fuji [77] 2009 Cirrhosis - - - - 0.76
Fibro Index Koda [106] 2007 Fibrosis 36 97 94 59 0.83
Fibrosis Index Ohta [113] 2006 Fibrosis 68 71 75 81 0.85
FibroTest Imbert-Bismut [26] 2001 Fibrosis 87 59 63 85 0.87
Cirrhosis
Bedosa [102] 2003 Fibrosis 27 97 90 55 -
Myers [101] 2003 Fibrosis - 95 88 - 0.83
Poynard [90] 2003 Fibrosis - - - - 0.73
Rossi [97] 2003 Fibrosis 83 52 52 83 0.74
Colletta [103] 2005 Fibrosis 64 31 33 62 -
Bourliere [80] 2006 Fibrosis 55 90 73 79 0.82
De Ledinghen [82] 2006 Cirrhosis - - - - 0.73
Halfon [83] 2007 Fibrosis 67 80 70 78 0.79
Cirrhosis 85 74 11 99 0.86
Leroy [84] 2008 Fibrosis 57 85 78 68 0.80
Cales [85] 2008 Fibrosis 67 82 80 70 0.81
Shaheen [104] 2008 Fibrosis 47 90 - - 0.81
Cirrhosis - - - - 0.90
Cales [105] 2010 Fibrosis - - - - 0.81
Cirrhosis - - - - 0.88
Forn’s Index Forn [27] 2002 Fibrosis 94 51 40 96 0.78
Cales [79] 2005 Fibrosis - - - - 0.82
Bourliere [80] 2006 Fibrosis 30 96 65 83 0.76
Koda [106] 2007 Fibrosis - - - - 0.79
Model 3 Lok [110] 2005 Cirrhosis 10 100 100 86 0.78
PGA Teare [87] 1993 Fibrosis 94 81 - - -
Cirrhosis - - 86 - -
Poynard [90] 2003 Fibrosis 91 81 - - -
Ahmad et al. Virology Journal 2011, 8:53
http://www.virologyj.com/content/8/1/53
Page 6 of 16extent to direct serum markers. APRI and FibroTest are
most validated serum markers with AUROC range
between 0.60-0.85 for predicting fibrosis and cirrhosis.
6. Composite fibrosis markers
6.1. FibroMeter
FibroMeter can differentiate fibrosis progression in viral
disease consist of combination of HA, AST, platelet
count, prothrombin index, alpha-2-macroglobulin, urea
and age of the patients [105].
6.2. Hepascore
Hepascore is a model consisting of bilirubin, GGT, HA,
alpha-2-macroglobulin, gender and age. AUROC of this
test is 0.85, 0.96 and 0.94 for significant fibrosis,
advanced fibrosis and cirrhosis, respectively [117-120].
6.3. Shasta Index
It combines HA, AST and albumin. Optimal results of
this assay are observed in extreme conditions. This
assay showed similar accuracy with FibroTest [121].
Table 2 Diagnostic accuracies of indirect serum markers (Continued)
Poynard [91] 2004 Fibrosis 79 89 - - -
PGAA Naveau [92] 2005 Cirrhosis 89 79 - - 0.93
Phol Score Pohl [114] 2001 Fibrosis 41 99 93 85 -
Cheung [115] 2008 Fibrosis - - - - 0.53
Table 3 Prognosis accuracies of combined serum markers
Markers Study Year Prognosis Sen Spe PPV NVP AUC
FIB-4 Sterling [122] 2006 Fibrosis 70 74 42 71 0.80
Cirrhosis
De Ledingh [82] 2006 Cirrhosis - - - - 0.73
Vallet-Pichard [123] 2007 Fibrosis 74 80 82 95 0.85
Cales [85] 2008 Fibrosis 74 72 74 71 0.80
Cirrhosis - - - - 0.87
Mallet [124] 2009 Fibrosis 71 73 52 86 0.81
Cirrhosis - - - - 0.87
Lee [107] 2010 Cirrhosis - - - - 0.71
Fibrometer Halfon [83] 2007 Fibrosis 92 87 21 100 0.94
Cirrhosis 62 87 21 100 0.94
Cales [85] 2008 Fibrosis - - - - 0.90
Cirrhosis - - - - 0.90
Cales [105] 2010 Fibrosis - - - - 0.88
Cirrhosis - - - - 0.88
Fortunato Score Fortunato [127] 2001 Fibrosis - 94 - - -
HepaScore Adams [117] 2005 Fibrosis 63 89 88 90 0.82
Cirrhosis 71 89 - - 0.90
Bourliere [80] 2006 Fibrosis - - - - 0.82
Cirrhosis - - - - 0.90
Halfon [83] 2007 Fibrosis 77 63 59 80 0.76
Cirrhosis 92 72 11 100 0.89
Leroy [118] 2007 Fibrosis 54 84 78 64 0.79
Leroy [84] 2008 Fibrosis 63 80 75 70 0.78
Cales [85] 2008 Fibrosis 66 79 77 68 0.78
Cirrhosis - - - - 0.90
Becker [119] 2009 Fibrosis 82 65 70 78 0.81
Cirrhosis - - - - 0.88
Cales [105] 2010 Fibrosis - - - - 0.78
Cirrhosis - - - - 0.89
Guechot [120] 2010 Fibrosis 77 70 71 77 0.81
Cirrhosis 86 74 37 97 0.88
Shasta Index Kelleher [121] 2005 Fibrosis 88 72 55 94 0.87
Sud Index Sud [125] 2004 Fibrosis 42 98 97 54 0.84
Testa Index Testa [126] 2006 Fibrosis 78 79 - - 0.80
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This assay combines four markers: AST, ALT, platelet
count and age. This index can predict significant fibrosis
in patients infected with HIV/HCV [122]. Later studies
validated this index not only in co-infected patients but
also in HCV infected patients [85,123,124].
6.5. Sud Index
This assay is also known as FPI comprises of age, AST,
cholesterol, insulin resistance and alcohol intake. This
index showed high specificity and PPV for detecting
advance fibrosis [125].
6.6. Testa Index
This index relate platelet count and spleen diameter.
This ratio showed 78% concordance with the histologi-
cal score [126].
6.7. Fortunato score
This model contains fibronectin, prothrombin time,
P C H E ,A L T ,M n - S O Da n db-NAG as essential compo-
nents. It has ability to classify cirrhotic from chronic
patients with high accuracy in initial and validation
cohort [127].
Table 3 gives an idea about the prediction levels of
combined serum markers. These markers showed high
AUROCs (0.80-0.90) for predicting fibrosis and cirrhosis
in HCV infected patients. FIB-4, Fibrometer and Hepa-
score are most precise and validated serum markers.
Combined serum markers are easily available and most
preferable non invasive serum markers now a day.
7. Imaging/scanning techniques
Imaging techniques are rational noninvasive approach to
assess liver fibrosis. Imaging techniques are not only
capable to detect changes in the hepatic parenchyma,
these can differentiate between moderate and severe
fibrosis. However, high cost and lack of validation of
concerning studies remains controversial. Brief detail of
these techniques is given under, while there limitations
are addressed in Table 4.
7.1. Ultrasonography (US)
Ultrasonography detects changes appear in liver echo-
genicity, nodularity and signs of portal hypertension.
A number of studies proposed the role of ultrasonogra-
phy as a non-invasive diagnostic marker of liver fibrosis
and revealed a great sensitivity of ultrasonography to
detect late stages of progressive hepatic fibrosis, but a
limited capability to measure mild or moderate fibrosis.
Ultrasound can identify cirrhosis in patients with sensi-
tivity of 84% and specificity of 100% and diagnose accu-
rately 94%. Shen et al. observed that the echo pattern of
the hepatic surface contributed to diagnostic accuracy,
which was also confirmed in a separate study. However,
Oberti found ultrasonography as weak diagnostic marker
when compared it with other clinical and biochemical
examinations [128-133].
7.2. Transient Elastography (FibroScan): an applicable
alternative to liver biopsy
Transient elastography measures tissue stiffness. It can
measure liver sample size 100 times greater than a stan-
dard biopsy sample size, as liver biopsy size strongly
effects the grading of chronic viral hepatitis [134-137].
FibroScan results reported 100% sensitivity and specifi-
city for PPV & NPV respectively (103). In a study of
935 patients Fibroscan was found to be 97% successful
in grading chronic HCV infection [138]. In another
study on 711 patients, liver stiffness measurements
(LSM) were also found closely related to fibrosis stage
[139]. Vizzutti et al. has also reported a good correlation
between liver stiffness measurement and HVPG (hepatic
venous pressure gradient) in cirrhotic patients. Success
rate depends on patient body mass index, observer
expertise and inter-coastal spaces with 5% failure
chances. Several authors assess the performance of elas-
tography and configure it best for the diagnosis of fibro-
sis [13,86,103,140-149]. A combination of FibroScan
with FibroTest also gives a better understanding to
detect fibrosis and cirrhosis with high AUC [104]. Table
5 briefly describes the diagnostic accuracy of FibroScan
with or without combination with FibroTest. In all
Table 4 Summarized imaging techniques with their limitations
Method Technique Limitations
Ultrasonography Identification of portal hypertension Limited capability to measure mild or moderate fibrosis and cirrhosis, contradictory
results
Elastography Liver stiffness Vulnerable measurements due to narrow intercostals spaces, ascites or obesity
Doppler Analysis Measures velocity of blood flow,
hemodynamic variations
Limited data, lack of reproducibility, contradictory results
Magnetic
Resonance Imaging
Observe changes in hepatic
parenchyma
High cost, lack of research support
Computed
Tomography
Identifies micro vascular permeability
changes
Recent technique, not much literature is available, can not performed in renal
failure and contrast agent allergic patients
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not more than liver biopsy (AUROC > 0.970).
7.3. Doppler analysis
Doppler measures the velocity of blood flow hemody-
namic variations in hepatic vasculature, as sever fibrosis
causes irregularities and abnormalities in hepatic blood
vessels. Recent data indicate a close correlation between
arterioportal ratio and degree of fibrosis, higher ratio
indicates severe fibrosis (F3-F4) and low ratio shows
moderate fibrosis (F1-F2) [150-153].
7.4. Magnetic resonance imaging (MRI)
MRI observes changes in hepatic parenchyma. Non-
invasive prognosis of liver cirrhosis is proposed by using
double contrast material-enhanced MR imaging. This
can detect cirrhosis with great sensitivity and specificity
of 90%. Combining Doppler ultrasonography with MRI
can give a good picture of liver fibrosis in patients suf-
fering with chronic HCV [154-156].
7.5. Computed tomography (CT)
CT identifies microvascular permeability changes in a
model of liver fibrosis. In a latest study, the severity of
liver fibrosis was predicted by heterogeneous enhance-
ment of the liver; hepatic parameters. Perfusion calcu-
lated with a dynamic contrast-enhanced single-section
CT, linked with the severity of chronic liver disease.
However, no well characterized study has specifically
evaluated the worth of CT in diagnosing degree of fibro-
sis. Therefore, currently its role in diagnosis of liver
fibrosis is still lacking [157-159].
7.6. Fibroscan + Fibrotest
The combination of two useful noninvasive methods,
fibroscan and fibrotest showed high AUROC for pre-
dicting cirrhosis [104,160].
7.7. Modified imaging techniques
Imaging techniques with modification like Real-time elas-
tography, Tissue strain imaging, Supersonic shear imaging,
Contrast enhanced MRI, Diffusion-weighted MRI, Mag-
netic resonance spectroscopy, Positron emission tomogra-
phy (PET), Single photon emission computed tomography
(SPECT) are also in use to evaluate liver fibrosis and cir-
rhosis with considerable limitations like, lack of data and
expertise, high cost, radiation exposure and short half-life
of the tracer in PET and SPECT.
8. Genetic markers for liver fibrosis evaluation
ECM metabolism is very dynamic process and required an
intricate balance between ECM deposition and removal.
Several genetic polymorphisms influenced by factors/cyto-
kines and affect fibrosis progression [98]. Genome-wide
analysis of abnormal gene expression showed transcript
deregulations during HCC development with identification
of novel serum markers differentiating between normal,
mild and severe fibrosis. Advantage of genetic markers
Table 5 Diagnostic accuracy of Fibroscan with and without FibroTest
Markers Study Year Prognosis Sen Spe PPV NVP AUC
Fibro Scan Ziol [13] 2005 Fibrosis 56 91 88 56 0.79
Cirrhosis 86 96 78 97 0.97
Colletta [103] 2005 Fibrosis 100 100 100 100 1.00
Foucher [139] 2006 Fibrosis 64 85 90 52 0.80
Cirrhosis 77 97 91 92 0.96
Corpechot [145] 2006 Fibrosis - - - - 0.95
Ganne-Carrie [146] 2006 Cirrhosis 79 95 74 96 0.95
Kettaneh [138] 2007 Fibrosis - - - - 0.79
Cirrhosis - - - - 0.91
Shaheen [147] 2007 Fibrosis 64 87 - - 0.83
Cirrhosis - - - - 0.95
Friedrich-Rust [148] 2009 Fibrosis - - - - 0.84
Cirrhosis - - - - 0.94
Kamphues [86] 2010 Fibrosis 72 83 96 58 0.81
Cirrhosis 100 65 23 100 0.87
Sanchez-Conde [149] 2010 Fibrosis 76 75 70 81 0.93
Cirrhosis 100 94 57 100 0.99
Fibro Scan + FibroTest Castera [160] 2005 Fibrosis - - - - 0.88
Cirrhosis - - - - 0.95
Shaheen [104] 2008 Fibrosis 47 90 - - -
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represents only one time point [161-163].
Huang and colleagues developed an assay known as
cirrhosis risk score (CRS), a set of seven marker genes
to predict cirrhosis risk in HCV infected patients. Of
the seven genes, AZIN1 and TLR4 have an identified
role in hepatic fibrosis, while the identification of func-
tional mechanism of the other 5 genes is under process.
The authors suggested that fibrosis risk can be identified
by host genetic factors like single nucleotide polymorph-
ism (SNP’s) [164,165].
A strong association betweenC X C R 3 - a s s o c i a t e dc h e -
mokines CXCL9 and CXCL10 with liver fibrosis sug-
gested that they may have promise as new non-invasive
markers of liver fibrosis in HCV infected patients
[166,167].
CTGF expression is significantly correlated with fibro-
sis stages and remarkably increased in advanced stages
in HCV patients. The AUROC of CTGF to discriminate
between mild and advanced fibrosis is 0.842 for HCV
infected patients [168].
Sharma et al. reported the significant association and
elevated interleukin-18 (IL-18) levels in fibrotic and cir-
rhotic liver stages, severity of disease and necrosis in
HCV patients [169].
A recent study by Caillot et al. used microarray tech-
nique and found a significant association of ITIH1, SER-
PINF2 and TTR genes expression and their related
proteins with all fibrosis stages. Expression of these
genes and related proteins gradually decreased during
the fibrosis development to its end stage cirrhosis [170].
A review by Gutierrez-Reyes et al. briefly described
role and selection of appropriate genes for fibrosis indi-
cation. They briefly explain the role of various genes
like PDGF, TGF-b1, collagens COL1-A1, TNFa, interlu-
kin, ADAMTS, MMPs, TIMPs, LAMB1, LAMC1, Cad-
herin, CD44, ICAM1, ITGA, APO and CYP2C8 [171].
Figure 2 represents gene clustering according to fibrosis
progression on available data.
9. Others markers for liver fibrosis evaluation
9.1. C-Caffeine Breath Test (CBT)
Caffeine has high oral bioavailability and undergoes
hepatic metabolism and can be use as quantitative test
for liver function [172]. Park et al. performed caffeine
breath test (CBT) and observed the correlation of orally
administrated caffeine with plasma caffeine clearance
and degree of liver dysfunction. Chronic patients
showed significantly reduced CBT values when com-
pared with controls [173].
9.2.Differentially expressed proteins
Differentially expressed proteins were identified by mass
spectroscopy among different degrees of fibrosis (F0-F4)
and between early (F0-F1) and late (F2-F4) fibrosis.
Mac-2-binding protein, alpha-2-macroglobulin and
hemopexin levels were found increased while A-1-anti-
trypsin, leucine-rich alpha-2-glycoprotein and fetuin-A
were decreased in advanced fibrosis F4 as compared to
early fibrosis F0/F1 [115].
10. Clinical utilization and future of non-invasive
markers
Non-invasive markers should be able to differentiate
between different fibrosis stages but also reflect the
treatment outcome. Even though the invasive liver biop-
sies considered as gold standard for final assessment of
liver fibrosis, non-invasive markers are risk free, reflect
the liver status and may offer an attractive alternative to
liver biopsy in future. However, none of currently avail-
able serum markers completely fulfill these criteria. The
outcome of non-invasive markers in several studies is
not same. Due to this, non-invasive markers are used in
parallel to liver biopsy and not in position to completely
replace liver biopsy till date.
Poynard et al. reported the effect of interferon plus
ribavirin before and after therapy with respect to
FibroTest and Actitest scores. A substantial reduction in
FibroTest and Actitest was observed in patients who
had showed a sustained virological response [81,90,115].
Several other studies reported the down level of serum
markers like HA, YKL-40, TIMP-1 and PIIINP after
interferon therapy. In these studies, level of serum
Figure 2 Genes expressed differentially between different
fibrosis stages (F0-F3) including cirrhosis (F4).
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Page 10 of 16markers continue to fall following treatment but most
often return to permanent levels with biochemical and
virological relapse. These f i n d i n g ss u g g e s tt h a tt h e s e
assays may be useful for initial staging of disease pro-
gression as well as histological response to therapy
[174-177]. Fibroscan showed positive correlation with
fibrosis stages. However, it is reported that AUROC
value of Fibroscan and FibroTest must be improved as
their values fall in treated patients irrespective of their
virological response [178,179]. Furthermore, HCV clear-
ance is associated with a significant reduction in non-
invasive fibrosis serological markers like FibroTest,
Forns Index, age-platelet ratio index, Shasta, FIB-4, Hepa-
score and FibroMeter [180]. Patel et al. compared two
commercially available serum marker panels Fibrosure
and Fibrospect-II in HCV patients during interferon-based
therapy. Both assays showed comparable performance for
differentiating mild fibrosis from moderate-severe stage
[181]. Imaging techniques also have some technical limita-
tions. These are very expensive and are not easy to handle.
Their presence in each hospital or laboratory is not possi-
ble especially in poor countries. On the other hand genetic
markers showed a great variability for detecting cirrhosis
and fibrosis. They are also able to differentiate among
fibrosis stages. But a lot of work is needed for them to
become an integral part of hepatic analysis.
11. Conclusions
Our study showed that there are only three to four mar-
kers or set of marker that are used continuously based
on their precision and accuracy in various studies for
fibrosis and cirrhosis prediction. In serum non-invasive
markers, FibroTest, Forn’s Index, Fibrometer and Hea-
p a S c o r eh a v eah i g hf i v e - y e a rp r o g n o s t i cv a l u eb u tn o t
compared to liver biopsy (AUROC = 0.97), while Fibros-
can showed maximum accuracy nearer to liver biopsy
(AUROC > 0.90). Recently, genetic markers showed dif-
ferential gene expression in different fibrosis stages, but
these are not frequently available in all labs. Imaging
techniques like ultrasound and elastography not only
used to diagnose liver fibrosis but also monitor disease
progression. However, genetic markers showed high
ability to distinguish not only mild and advance stages
of liver fibrosis but also differentiate between intermedi-
ate fibrosis stages. Although present published literature
do not provide any evidence for non-invasive markers to
become an integrated part of the complete assessment
of liver fibrosis in HCV patients, a combination of two
or more serum markers with imaging techniques may
improve the accuracy of diagnosis.
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